PESO, CUORE E RINASCITA: IL NUOVO ORIZZONTE DEL GLP-1RA

1. 1.Thomsen RW, Mailhac A, Løhde JB, Pottegård A.. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025
   Articolo scientificoDiabetes Obes MetabLeggi il paperCerca versione gratuita
2. 2.A. Michael Lincoff, Kirstine Brown-Frandsen, Helen M. Colhoun, John Deanfield, Scott S. Emerson,., Sille Esbjerg, Søren Hardt-Lindberg. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. SELECT Trial Investigators. 2023
   Articolo scientificoSELECT Trial InvestigatorsLeggi il PDF gratuito
3. 3.Kosiborod MN, Deanfield J, Pratley R, et al.. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024
   Articolo scientificoLancetLeggi il paperCerca versione gratuita
4. 4.Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS.. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.. 2023
   Articolo scientificoPharmacotherapy of obesity: an update on the available medications and drugs under investigation.Leggi il PDF gratuito

I link ai libri possono contenere un codice affiliato Amazon: in qualità di affiliato, ECM Finder potrebbe ricevere una commissione sugli acquisti idonei, senza alcun costo aggiuntivo per te. I link ai paper rimandano alla fonte scientifica (DOI, versione open-access o ricerca accademica).